the presence of monoamines and their cofactors (the pterins and vitamin B 6 (pyridoxal phosphate (plp))) in human cerebrospinal fluid (csF) can be used as indicators of the biosynthesis and turnover of dopamine and serotonin in the brain. In addition, abnormalities in the csF levels of these molecules are associated with various neurological diseases, including genetic diseases leading to dopamine and serotonin deficiency. Here, we provide a set of quantitative high-performance liquid-chromatography (Hplc) approaches to determine csF levels of monoamines and their cofactors. this protocol describes step-by-step procedures for csF sample preparation for the analysis of different molecules, Hplc calibration and analysis, and data quantification and interpretation. unlike plasma/tissue/blood samples, csF requires minimal sample preparation: in this protocol, only the analysis of plp requires mixing with trichloroacetic acid to release the protein-bound vitamin, centrifugation, and mixing of the supernatant with phosphate buffer and sodium cyanide for derivatization in alkaline conditions. Monoamines are analyzed by Hplc with coulometric electrochemical detection (eD), pterins are analyzed by Hplc with coupled coulometric electrochemical and fluorescence detection, and plp is analyzed by Hplc with fluorescence detection. the quantification of all compounds is achieved by external calibration procedures, and internal quality control and standards are analyzed in each run. We anticipate that investigation of dopamine and serotonin disturbances will be facilitated by measurements of these compounds in human csF and other biological samples. the estimated time for the different procedures primarily depends on the electrochemical detector stabilization. overnight stabilization of this detector is advised, and, after that step, preanalytical equilibration rarely exceeds 3 h.
IntroDuctIon
Monoamines such as dopamine and serotonin have fundamental roles in motor, perceptual, cognitive and emotional brain functions, along with other functions, including vascular tone, temperature regulation, endocrine regulation and swallowing 1 . The relevant pathways for their synthesis and disease-associated genetic defects are shown in Supplementary Figure 1 and Supplementary Table 1. Several genetic and environmental conditions have been shown to affect the metabolism of dopamine and serotonin or the cofactors that are essential for the proper biosynthesis of these monoamines (pterins and PLP) 1 . Aromatic l-amino acid decarboxylase and tyrosine hydroxylase deficiencies are two relevant genetic diseases (see also Supplementary  Fig. 1 and Supplementary Table 1 ). The quantitative detection of monoamines and their cofactors in the CSF can be used as an indicator for dopamine and serotonin biosynthesis and turnover in the brain, and it is considered to be an important diagnostic marker for a number of the conditions described above. The status of the dopamine and serotonin systems in the CNS can, for instance, be studied by measuring the levels of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA), respectively 2, 3 . The CSF concentrations of these primary (and stable) end metabolites provide insights into the biosynthesis and turnover of dopamine and serotonin. Screening for other dopamine and serotonin metabolites can be done in the same chromatogram, enabling a deeper investigation of the monoamine status in a single analysis 2, 3 . These metabolites are 3-orthomethyldopa (3-OMD) and methoxyhydroxyphenylglycol (MHPG) for the dopamine pathway and 5-hydroxytryptophan (5HTP) for the serotonin pathway (Fig. 1) . In addition, quantitative assessment of the CSF concentrations of cofactors that are essential for monoamine synthesis can provide important diagnostic information. Pterins (neopterin, dihydrobiopterin (BH 2 ) and tetrahydrobiopterin (BH 4 )) are, for example, useful biomarkers for the research of BH 4 -metabolism-associated genetic disorders. Neopterin analysis is a powerful tool for identifying inflammatory and immune conditions in the CNS 4 . Determining CSF PLP concentrations provides insights into the various genetic and environmental conditions that lead to a brain PLP deficiency 5 , which consequently affects dopamine and serotonin biosynthesis. In this protocol, we will describe several HPLC-based biochemical methods for the quantification of CSF concentrations of the aforementioned biomarkers ( Table 1) . The monoamine quantification procedures specified here can also be adapted for the quantification of other monoamines for diagnostic and research purposes. In addition, this methodology can be used for the investigation of neurotransmission status in both animal and cellular models, and for the analysis of plasma and urine samples.
Overview of the procedures
The first critical step toward studying the aforementioned compounds is the CSF sample collection procedure. For most of the diseases shown in Supplementary Table 1, analyses of blood or urine sample are unreliable for brain dopamine and serotonin status estimations. CSF collection should be performed by an expert clinician, and strict adherence to the preanalytical protocol is mandatory 6, 7 .
For the chromatographic separation of the biomarkers presented here, different HPLC methods are used: ion-pair HPLC is based on the modification of a reverse-phase column to separate ionized compounds. Reverse-phase HPLC allows the separation of compounds by hydrophobic interactions with the stationary phase of the column. With regard to detection, electrochemical detection (ED) is used to quantify redox active compounds by applying a potential and measuring the resulting current produced, which is proportional to the concentration. Fluorescence detection (FD) is used for the quantification of compounds with either native (pterin analysis) or derivatized fluorescent groups (PLP analysis). In FD, the compound is excited at one wavelength (excitation) and measured at another wavelength (emission) (see Table 2 for details).
For CSF monoamine quantification ( Step 1A of the PROCEDURE), ion-pair HPLC with coulometric ED (HPLC-ED) is the gold standard, because it enables a highly sensitive separation and quantification of these compounds 2, 7 .
For CSF pterin analysis, HPLC with FD (HPLC-FD) is a single approach for the rapid quantification of the oxidized pterins (neopterin, biopterin, primapterin and sepiapterin) as an estimation of the biosynthesis and metabolism of the active pterin (BH 4 ). This procedure has previously been reported in detail 3 and will not be included in this protocol. In-line HPLC-ED-FD ( Step 1B of the PROCEDURE) is also available for the quantification of total neopterin, BH 4 and its precursor, BH 2 , and it will be detailed in this report 3 . This in-line method allows the simultaneous quantification of both electroactive (BH 4 approach for PLP quantification 8, 9 . The results for each technique are reported as absolute values in the nanomole-per-liter range.
Applications of the method
The most common applications of the methods described here include the diagnosis of primary genetic conditions that lead to neurotransmitter deficiencies and other severe early-onset neurological diseases that can be associated with disturbances in brain dopamine and serotonin availability 10, 11 . The procedures may also be suitable for the quantification of monoamines such as dopamine, serotonin and related compounds in experimental animal and cellular models after adequate sample extraction and purification steps (acid precipitation on ice, centrifugation and supernatant filtration), as previously reported [12] [13] [14] . Brain microdialysis procedures also allow the determination of the levels of monoamines and other molecules in interstitial tissue fluid 15 . Fukushima et al. reported several works studying BH 4 and its metabolites by HPLC with FD in different rat tissues (pineal, liver, adrenal, brain and blood), showing that the same methodology is also useful for human samples (blood and urine) 11 . Elution and quantification of other monoamines are expected to occur in the same chromatogram as the key monoamines' metabolites of interest (Fig. 1) . For the pterins, applications beyond identification of primary genetic causes of BH 4 deficiency may include studies of brain inflammatory/immune events by CSF neopterin quantification. An analysis of PLP can detect suboptimal vitamin B 6 status due to nutritional deficiencies, increased turnover, increased sequestration by chemical adducts, and other environmental and genetic conditions that promote its deficiency 5, 16, 17 .
Comparison with other commonly used methods
The methods described here have been routinely used to investigate biogenic amines and pterins in the CSF. Ultra-HPLC-tandem mass spectrometry (UHPLC/MS-MS) methods are increasingly used in bioanalytical investigations, owing to their sensitivity, specificity and efficacy in different biological materials 18 . A targeted metabolomics approach is a noteworthy alternative to HPLC-based strategies, and new developments toward future human diagnostic applications are expected. Kovac et al. developed a LC/MS method to assess 5-hydroxytryptamine, 5HIAA, HVA, noradrenaline, adrenaline, dopamine, glutamate, γ-aminobutyric acid, 3,4-dihydroxyphenylacetic acid and histamine in the CSF of a rat model 18 . Santos-Fandila et al. described an analysis of neurotransmitters, metabolites and derivatives in rat microdialysates by UHPLC-MS/MS 19 . LC-MS/MS has also been used for pterin analyses and involves simultaneous detection of BH 4 , BH 2 and biopterin in urine samples, cell extracts and the rat brain [20] [21] [22] . However, according to the aforementioned authors, MS/MS detection is less sensitive than FD for pterin quantification. For PLP, a UHPLC-MS/MS approach has been published 23, 24 that allows the identification of seven vitamin B 6 vitamers in human CSF samples, although this procedure is not routinely used for PLP quantification in biological fluids. Recently, a simultaneous measurement of monoamine metabolites, and also 5-methyltetrahdyrofolate, in CSF by HPLC-FD has been developed 25 .
Taken together, the methodological information presented in this work may be very helpful to both clinical and basic research laboratories.
Limitations
Practical limitations in sample preparation are worthy of consideration. First, sometimes the sample volume is not sufficient to allow all of the investigations required. Moreover, CSF contamination by blood after traumatic lumbar puncture may cause autoxidation of some compounds (such as monoamines 26 ). Regarding CSF matrix effects, they are less important than those of blood or other tissues, and they have been reported to be mainly associated with mass spectrometry procedures. The main limitations of the present protocol are related to the HPLC-ED system. Although HPLC-FD is robust and highly sensitive, HPLC-ED requires an optimum equilibration and preparation of the system, and requires specifically trained operators, so it may be relatively timeconsuming. These issues and other ones will be discussed in the present protocol. The establishment of accurate reference values is mandatory for proper data interpretation. CSF samples from 'healthy' pediatric controls are needed, but these samples are difficult to collect outside the hospital setting. Because there is a strong correlation between the monoamine, pterin and PLP levels and age, a large CSF sample size is required for the establishment of reference values, as several intervals must be defined. We took advantage of the lumbar punctures collected in our hospitals for viral and bacterial meningitis diagnoses. Once these diseases were ruled out, we used the remaining samples as control samples to determine levels of biogenic amines, pterins and PLP.
Level of expertise
These analytical procedures can be performed by competent professionals. The most complicated procedure involves ED, and special training for those managing the electrochemical detector is advisable. However, the critical step involves data interpretation because a high degree of experience is required to identify the genetic conditions mentioned in Supplementary Table 1 and to interpret the numerous secondary neurotransmitter, pterin and PLP disturbances. Therefore, data interpretation should be performed within the context of the clinical information provided by an expert clinician in the field. 
Experimental design
The optimization of the biogenic amine, pterin and PLP measurements is divided into two stages as follows: (i) preanalytical factors (sample collection and storage protocol) and (ii) analytical factors (optimization of the HPLC-ED and FD settings, and data interpretation).
Preanalytical factors. CSF is the ideal biological sample for diagnosing most biogenic amine disorders. A protocolized lumbar puncture collection is required for a reliable analysis of the monoamines, pterins and PLP ( Table 3) . Because there is a rostrocaudal gradient (i.e., the concentration of some metabolites is higher in the final CSF fractions than in the initial fractions), it is important to compare a patient's values to his/her own reference values, which are established using the same CSF fraction 6, 7 .
Because red blood cell lysis causes oxidation of amine metabolites, blood-contaminated samples must immediately be centrifuged, and the clear CSF supernatant must be transferred to a new tube.
To measure neopterin, BH 2 and BH 4 , the CSF sample must be protected from light and stored with stabilizing agents, because the reduced forms are extremely light-and oxygen-sensitive 3 . Because CSF samples have fewer interfering compounds as compared with other biological matrixes, such as blood, plasma, tissue extracts or urine, no extensive purification or extraction procedures are required, and only single dilution and filtration steps are needed before HPLC analysis 7 . However, guard column and graphite filters must be regularly replaced to assure a good analytical performance. Sample storage at −70 °C with protection from light is mandatory (Table 3) .
Analytical factors for monoamine quantification. HPLC-ED is the most commonly used procedure for monoamine quantification. This approach is based on ion-pair chromatography separation, with a mobile phase consisting of a citrate-acetate buffer at an acidic pH that is supplemented with an ion-pair agent (heptanosulfonic acid or equivalent) 6, 7 . The ion-pair agent has an ionic head group and a nonpolar tail. The nonpolar tail interacts strongly with the C18 column, whereas the ionic head group is projected into the mobile phase. This column modification generates an attraction between ion-pair agent and ionized compounds, allowing chromatographic retention and elution. Critical separation conditions that can markedly change a compound's elution time include the pH value of the mobile phase and the ion-pair agent 27 . The detection of monoamines is mediated by coulometric ED. In this approach, the electrochemical detector is used to determine the current generated between two electrodes placed in the detection cell. These electrodes are the working electrode (E1), in which the current is generated, and the auxiliary (E2, or counter) electrode, in which the complementary electrolytic reaction takes place. The potential between the electrodes is held constant, resulting in the complete oxidation of the analyzed compounds of interest. Another electrode, called the reference electrode, is used to keep the potential stable throughout the measurements. The appropriate ED settings are very important to achieving complete oxidation of the analyte. The appropriate potential for ED can be determined by measuring the oxidative current of the analyte (at a constant concentration) over a range of working electrode potentials. The plot of current generated versus applied potential is called the hydrodynamic voltammogram. We advise collecting a hydrodynamic voltammogram plot regularly for each compound, as different variables may influence the results, including factors such as the mobile-phase composition, the type and age of electrodes used and the deterioration of the graphite filter with time 28 . The applied potential at +450 mV is normally A current/voltage plot is generated after injecting a constant sample volume, which is measured after fixing different potentials. The lowest current that produces the highest analytical response to the electrode should be chosen.
Box 1 | Electrochemical cell cleaning procedure • TIMING 40 min-2 h
Disconnect the cell from the control module and from the HPLC system. Using a flushing syringe, flush the cell with the solutions indicated below (5-10 ml of each). 1. For general cleaning, flush the cell with deionized water/methanol/deionized water for 10 min at 1 ml/min (pH >5). 2. For lipophilic materials, flush with deionized water/methanol/acetonitrile/THF/acetonitrile/methanol/deionized water at a rate of 1 ml/min for 10 to 15 min each. ! cautIon NaOH, organic solvents and nitric acid can cause personal injury. Use eye protection and protective clothing, and perform flushing in in a fume hood. 3. For organic materials, flush the system with deionized water/DMSO/deionized water at 1 ml/min for 10 min each. 4. Silica from the column is flushed with deionized water for 10 min at 1 ml/min. Then, using a syringe, the cell is filled with 2 M NaOH (leave it in the cell for 10-30 minutes). Finally, the cell is flushed with deionized water for 10 min at 1 ml/min (until pH is <7). 5. Oxidation/reduction cycle cleaning. Replace the mobile phase with freshly prepared 50 mM phosphate buffer at pH 3, flowing at 1 ml/min. Apply a potential of +1,000 mV to the electrode for 10 min with the phosphate buffer flowing. Do not recycle the phosphate buffer during the treatment. After the treatment, apply a potential of −400 mV for 10 min and then again apply a potential of +1,000 mV for 30 min. Reset the potentials to the assay's working potentials and test the response. 6. If these procedures do not work, clean the cell with nitric acid as a last resort. Flush the cell with deionized water for 10 min/nitric acid (leave in the cell for 15-30 min)/deionized water (for another 10 min at 1 ml/min) until the pH is >5. After this procedure, it will be necessary to determine the optimum oxidation potential of the compounds of interest by obtaining a new hydrodynamic voltammogram.
enough for the proper electrochemical oxidation of monoamines. This oxidation results in a current that can be sensed by the detector and is directly proportional to the monoamine concentration. An example of a hydrodynamic voltammogram is shown for 5HIAA and HVA in Figure 2 . Ideally, the lowest current that produces the highest analytical response to the electrode should be chosen, as this leads to a lower background signal. Regarding the composition of electrodes, we used porous graphite electrodes, as they have a large surface area. This permits the eluent to flow through the electrodes and thereby maximizes the contact area with electroactive compounds, increasing the sensitivity of the analysis. Special precautions should be taken for ED cell stabilization, maintenance and cleaning, which are described in the Equipment Setup section and Box 1. Analytical factors for PLP quantifipseccation. CSF PLP quantification is performed by HPLC with FD, as previously reported 8, 9 . The mobile phase consists of a phosphate buffer. PLP is derivatized with sodium cyanide under alkaline conditions. The analytical details of these procedures are summarized in Flasks and bottles, 5, 4, 2 and 1 liters ± 0.4; 500 ml ± 0.250; and 10 ml ± 0.02 Graduated cylinders, 100 ± 0.5 ml and 1,000 ± 5 ml (Labbox) Glass pipettes, 5 ± 0.045 ml and 2 ± 0.015 ml (Daslab; Nirco)  crItIcal Glassware calibrations by an external accredited company are essential to the preparation of the calibration solutions. 3-ml Polypropylene round-bottom tube (11 × 55 mm; Daslab; Nirco, cat. no. 175594) Filtering membrane filters, nylon, 0.45-µm pore size and 47-mm diameter, package of 50, for mobile-phase filtering (Teknokroma, cat. no. NY 504700) 4-mm syringe filter (for 2.5-ml plastic syringes; Ico Plus3; Novico Medica, cat. no. N15649) Hydrophilic PVDF membrane (0.22-µm pore size; Millex-GV; Merck Millipore, cat. no. SLGVR04NL) 10-kDa centrifugal filters for nonsterile filtration of the samples (Nanosep 10K Omega; Pall Life Sciences, cat. no. OD010c34) HPLC vials, 1-ml amber glass shell vial with a polyethylene snap cap (Waters, cat. no. 025053C) Vial insert, 150-µl glass insert with polymer feet (Agilent, cat. no. 5183-2088) Heat cabinet for PLP sample preparation (Conterm Poupinel; Selecta, cat. no. 2000200) REAGENT SETUP CSF sample collection An overview of the CSF samples we collect and the required volumes is summarized in Table 3 . Additional biomarkers, such as amino acids, can be determined in the CSF samples, and it is important to use this advantage. CSF samples are collected in conventional plastic tubes (10-ml round-bottom polystyrene tubes) without preservatives, except for the pterins. For the pterin analysis, the sample must be collected into a microcentrifuge tube that contains dithioerythritol (1 mg) and diethylenetriaminepentaacetic acid (1 mg) (antioxidants). The sample volume estimation by drop number is useful for the clinician in charge of the CSF collection, because the liquid leaves the spine drop by drop. Critical factors for consideration when collecting CSF samples include the rostrocaudal gradient, time of sample collection, and protection from light and blood contamination. Immediately after collection, the tubes (particularly tubes 2-4) must be placed on dry ice and frozen immediately at −70 °C in the dark. If CSF is contaminated with blood, centrifuge the CSF samples (1,500g × 10 min at 4 °C) and store the clear supernatant. Patient CSF samples can be stored for at least 10 years at −70 °C. ! cautIon The lumbar puncture is an invasive procedure, and critical factors should be considered.
MaterIals

REAGENTS
• Pterin BH 4 standard(500 µM) In a 100-ml volumetric flask, add 100 ± 0.1 mg of DTE and DETAPAC to 80 ml of water and sonicate the mixture for 5 min to ensure that the DETAPAC has completely dissolved. Dissolve 15.7 ± 0.1 mg of BH 4 in the mixture and bring the final volume to 100 ml with water. Mix the solution on ice for 30 min with a stir bar and a magnetic stirrer (in the dark), and then prepare 0.5-ml aliquots.  crItIcal The 0.5-ml aliquots should be transferred to Eppendorf tubes and immediately frozen at −70 °C. The aliquots can be stored for up to 1 year. Pterin d-neopterin standard(500 µM) Prepare a 10 M NaOH solution by dissolving 10.0 ± 0.1 g of NaOH in 25 ml of water. Slowly add NaOH while cooling on ice. Dissolve 10 µl of 10 M NaOH and 12.70 ± 0.04 mg of d-neopterin in 80 ml of water in a foil-wrapped volumetric flask. Bring the volume to 100 ml and mix the solution on ice for 30 min using a magnetic stirrer (in the dark). Then prepare 0.5-ml aliquots.  crItIcal The 0.5-ml aliquots should be transferred to Eppendorf tubes and immediately frozen at −70 °C. The frozen aliquots can be stored for up to 1 year. Because of their light and temperature sensitivities, the 500 µM stock solutions for BH 4 and D-neopterin should be prepared in foil-wrapped volumetric flasks and stored on ice. Pterin BH 2 standard(500 µM) Dissolve 80 µl of 10 M NaOH and 11.96 ± 0.04 mg of BH 2 in 80 ml of H 2 O in a foil-wrapped volumetric flask. Bring the volume to 100 ml with water and mix the solution for 30 min on ice using a magnetic stirrer (in the dark). Then prepare 0.5-ml aliquots.  crItIcal The 0.5-ml aliquots should be transferred to Eppendorf tubes and immediately frozen at −70 °C. The aliquots can be stored for up to 1 year. Pterin standard diluent Dissolve 25 ± 0.04 mg of DTE and 2.5 ± 0.04 mg of DETAPAC in 25 ml of water. Sonicate the mixture for 5 min to ensure DETAPAC dissolution. This solution can be stored for up to 1 year at −70 °C. Pterin working standard Pour ~8 ml of the standard diluent into a 10-ml volumetric flask. Add 100 µl of each BH 4 , BH 2 and neopterin stock standard, and bring the volume to 10 ml with the standard diluent. Thoroughly mix the contents of the flask by inversion. Fill another 10-ml volumetric flask with ~8 ml of the standard diluent, and add 100 µl of the first stock standard dilution. Bring the volume to 10 ml, and thoroughly mix the contents of the flask by inversion. Steps iii-xii, HPLC-ED-FD setup: 3 h (1 h to prepare the HPLC system and 2 h to equilibrate the system). Overnight equilibration is advisable (flow rate 0.3 ml/min). The next day, restore the flow rate to 1.3 ml/min at least 1 h before starting the analysis, in order to stabilize the HPLC system.
Steps xiii-xv, data acquisition and analysis: 25 min per sample (20 min for running the sample and 5 min for chromatographic data analysis) option c: plp analysis Steps i-vii, standard, control and sample preparation: 40 min Steps viii-xvii, HPLC-FD setup: 2 h (30 min to prepare the HPLC system and 1.5 h to equilibrate the system) Steps xviii-xx, data acquisition and analysis: 30 min per sample (25 min for running the sample and 5 min for chromatographic data analysis)
antIcIpateD results
The procedures described in this protocol will provide suitable methods for determining the concentration of monoamines and their cofactors (the pterins and PLP) in CSF samples. Typical chromatograms of human CSF monoamines are shown together with those for the calibration mixtures in Figure 4 . A rapid identification of primary genetic or secondary conditions that lead to dopamine and serotonin disturbances is expected, as previously reported 4, 29 . Four additional chromatograms depicting the neopterin, BH 4 and BH 2 (Fig. 5 ) results in calibration mixtures and human CSF samples are shown. A chromatogram displaying the PLP calibration and a human CSF sample for the PLP analysis is also presented (Fig. 6 ).
An experiment that required troubleshooting to improve the analytical qualities is presented in Figure 7 . coMpetInG FInancIal Interests The authors declare no competing financial interests.
